Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study
Yuan Cheng, Binghua Li, Decai Yu · 2026
Read Fatty Acid Degradation (FAD) Subtype-Informed Treatment Allocation in Unresectable Hepatocellular Carcinoma (FAD-HCC-01): Protocol for a Prospective Multicentre Proof-of-Concept Study by Yuan Cheng, Binghua Li, Decai Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13186218.txt.
Description
Yuan Cheng, Binghua Li, and Decai Yu set out a 2026 protocol for a trial in liver cancer that cannot be cut out. Tumors of this kind vary a lot in biology, so drug response varies too. Gene signatures tied to fat breakdown split the cancer into subtypes with unlike immune traits and weak points.
Past record reviews hint that some subtypes gain more from immune based drug care, while another may answer better to a vessel directed procedure. The planned study will sort new patients by subtype and assign care on that basis. It runs at many centers as an open proof of concept trial. The aims are to test if the sorting is workable and to get an early read on patient outcomes.
Catalog record
| CREATOR | Yuan Cheng, Binghua Li, Decai Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |